Prevention of Depression With Escitalopram in Patients Undergoing Treatment for Head and Neck Cancer<subtitle>Randomized, Double-blind, Placebo-Controlled Clinical Trial</subtitle><alt-title>Escitalopram for Depression Prevention</alt-title>
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
IMPORTANCE: Major depressive disorder develops in up to half the patients undergoing treatment for head and neck cancer, resulting in significant morbidity; therefore, preventing depression during cancer treatment may be of great benefit. OBJECTIVE: To determine whether prophylactic use of the antidepressant escitalopram oxalate would decrease the incidence of depression in patients receiving primary therapy for head and neck cancer. DESIGN, SETTING, AND PARTICIPANTS: A randomized, double-blind, placebo-controlled trial of escitalopram vs placebo was conducted in a group of nondepressed patients diagnosed as having head and neck cancer who were about to enter cancer treatment. Patients were stratified by sex, site, stage (early vs advanced), and primary modality of treatment (radiation vs surgery). MAIN OUTCOME AND MEASURE: The primary outcome measure was the number of participants who developed moderate or greater depression (scores on the Quick Inventory of Depressive Symptomology-Self Rated of ≥11). RESULTS: From January 6, 2008, to December 28, 2011, 148 patients were randomized. Significantly fewer patients receiving escitalopram developed depression (24.6% in the placebo group vs 10.0% in the escitalopram group; stratified log-rank test, P = .04). A Cox proportional hazards regression model compared the 2 treatment groups after controlling for age, baseline smoking status, and stratification variables. The hazard ratio of 0.37 (95% CI, 0.14-0.96) demonstrated an advantage of escitalopram (P = .04). Patients undergoing radiotherapy as the initial modality were significantly more likely to develop depression than those undergoing surgery (radiotherapy compared with surgery group; hazard ratio, 3.6; 95% CI, 1.38-9.40; P = .009). Patients in the escitalopram group who completed the study and were not depressed rated their overall quality of life as significantly better for 3 consecutive months after cessation of drug use. CONCLUSIONS AND RELEVANCE: In nondepressed patients undergoing treatment for head and neck cancer, prophylactic escitalopram reduced the risk of developing depression by more than 50%. In nondepressed patients who completed the trial, quality of life was also significantly better for 3 consecutive months after cessation of drug use in the escitalopram group. These findings have important implications for the treatment of patients with head and neck cancer. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00536172.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
Rush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
Paroxetine for the prevention of depression induced by high-dose interferon alfa.
Musselman, D. L., Lawson, D. H., Gumnick, J. F., Manatunga, A. K., Penna, S., Goodkin, R. S., Greiner, K., Nemeroff, C. B., & Miller, A. H. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103293441303 · Cited by 1,120
Cytokines and their relationship to the symptoms and outcome of cancer
Seruga, B., Zhang, H., Bernstein, L. J., & Tannock, I. F. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2507 · Cited by 652
Osborn, R. L., Demoncada, A. C., & Feuerstein, M. (2006) · The International Journal of Psychiatry in Medicine · doi:10.2190/eufn-rv1k-y3tr-fk0l · Cited by 621
Aspirin for Preventing the Recurrence of Venous Thromboembolism
Becattini, C., Agnelli, G., Schenone, A., Eichinger, S., Bucherini, E., Silingardi, M., Bianchi, M., Moia, M., Ageno, W., Vandelli, M. R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114238 · Cited by 620
Incidence of Suicide in Persons With Cancer
Misono, S., Weiss, N. S., Fann, J. R., Redman, M., & Yueh, B. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.8941 · Cited by 608
Son, H., Banasr, M., Choi, M., Chae, S. Y., Licznerski, P., Lee, B., Voleti, B., Li, N., Lepack, A., Fournier, N. M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201191109 · Cited by 103
Alme, M. N., Wibrand, K., Dagestad, G., & Bramham, C. R. (2007) · Neural Plasticity · doi:10.1155/2007/26496 · Cited by 103
Kocsis, J. H., Thase, M. E., Trivedi, M. H., Shelton, R. C., Kornstein, S. G., Nemeroff, C. B., Friedman, E. S., Gelenberg, A. J., Dunner, D. L., Hirschfeld, R. M. A., et al. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0706 · Cited by 67
Cited by
The current state of the neurogenic theory of depression and anxiety
Miller, B. R., & Hen, R. (2015) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2014.08.012 · Cited by 386
Smith, J. D., Shuman, A. G., & Riba, M. B. (2017) · Current Psychiatry Reports · doi:10.1007/s11920-017-0811-9 · Cited by 81
Henry, M., Rosberger, Z., Bertrand, L., Klassen, C., Hier, M., Zeitouni, A., Kost, K., Mlynarek, A., Richardson, K., Black, M., et al. (2018) · Otolaryngology–Head and Neck Surgery · doi:10.1177/0194599818776873 · Cited by 76
“Our first objective was to determine the 1-year period prevalence of suicidal ideation, suicide attempt, and completed suicide among patients newly diagnosed with a first occurrence of HNC.”
BackgroundInfluentialEllis, M. A., Sterba, K. R., Brennan, E. A., Maurer, S., Hill, E. G., Day, T. A., & Graboyes, E. M. (2019) · Otolaryngology–Head and Neck Surgery · doi:10.1177/0194599819829018 · Cited by 56
Zahid, J. A., Grummedal, O., Madsen, M. T., & Gögenur, I. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.10.009 · Cited by 48
Metadata
- Authors
- Lydiatt, W. M.
- Venue
- JAMA Otolaryngology–Head & Neck Surgery
- Publisher
- American Medical Association (AMA)
- Published
- 2013-06-20
- Volume
- 139
- Issue
- 7
- Pages
- 1
- ISSN
- 2168-6181 (ISSN-L)
- OpenAlex
- W1853931894
- Cited by
- 82
- References
- 10
- FWCI
- 3.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevention of Depression With Escitalopram in Patients Undergoing Treatment for Head and Neck Cancer<subtitle>Randomized, Double-blind, Placebo-Controlled Clinical Trial</subtitle><alt-title>Escitalopram for Depression Prevention</alt-title>. https://app.cochat.ai/papers/10.1001/jamaoto.2013.3371
- The paper
- Lydiatt, W. M. (2013). Prevention of Depression With Escitalopram in Patients Undergoing Treatment for Head and Neck Cancer<subtitle>Randomized, Double-blind, Placebo-Controlled Clinical Trial</subtitle><alt-title>Escitalopram for Depression Prevention</alt-title>. JAMA Otolaryngology–Head & Neck Surgery. https://doi.org/10.1001/jamaoto.2013.3371
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.